FD Technologies Regulatory News (FDP)

17 May 2019

First Derivatives plc

("FD" or the "Group")

Statement regarding Brian Conlon

FD (AIM: FDP.L, Euronext Growth: FDP.I) announces that Brian Conlon, Chief Executive Officer, has recently been diagnosed with cancer. Brian will remain as Chief Executive Officer during his ongoing weekly treatment, which includes chemotherapy. This treatment is expected to last a number of months.

Seamus Keating, Chairman of FD, said: "The Board has set a clear strategy and the Executive Committee, led by Brian, has delivered strong execution of that strategy year-on-year. During the period of his treatment I will provide additional executive and governance support and I am confident that Brian and his team will continue to execute the Group's growth plans successfully."

Enquiries

For further information please contact:

About FD

FD is a global technology provider with 20 years of experience working with some of the world's largest finance, technology, retail, pharma, manufacturing and energy institutions. The Group's Kx technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. FD operates from 14 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,400 people worldwide.

For further information, please visit www.firstderivatives.com and www.kx.com